Sacubitril/valsartan (Entresto) for chronic heart failure; brexpiprazole 
(Rexulti) for major depressive disorder and schizophrenia; and 
lumacaftor/ivacaftor (Orkambi) for cystic fibrosis involving specific CFTR 
mutations.